Viatris
VTRS
$16.80
+0.60%
Viatris is a global healthcare company formed in 2020 through the merger of Mylan and Pfizer's Upjohn division, specializing in generic and specialty pharmaceuticals. It is one of the world's largest generic drug manufacturers, with a portfolio that includes legacy brands like Lipitor and Viagra, and a strategic focus on dermatology, ophthalmology, and gastroenterology. The current investor narrative centers on Viatris's turnaround efforts, including debt reduction, margin improvement, and the potential for biosimilar growth, as the stock has rallied over 78% in the past year amid improving sentiment.…
VTRS
Viatris
$16.80
VTRS 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Viatris's 12-month outlook, with a consensus price target around $21.84 and implied upside of +30.0% versus the current price.
Average Target
$21.84
2 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
2
covering this stock
Price Range
$13 - $22
Analyst target range
Only 2 analysts cover Viatris, with a consensus leaning bullish: one Overweight (Barclays) and one Neutral (Piper Sandler), and an upgrade from Hold to Buy by Argus Research in January 2026. The average target price is not provided, but based on the limited coverage, the implied upside/downside cannot be calculated precisely. The lack of extensive analyst coverage suggests Viatris is a mid-cap stock with less institutional attention, which can lead to higher volatility and less efficient price discovery. The wide range of ratings from Underweight to Overweight indicates uncertainty about the company's turnaround. The recent upgrade by Argus and maintained Overweight by Barclays suggest improving sentiment, while the Neutral stance from Piper Sandler reflects caution. Investors should monitor earnings and debt reduction progress for catalysts.
VTRS Technical Analysis
Viatris is in a sustained uptrend, with the stock price up 78.8% over the past year. The current price of $16.70 sits at 95.2% of its 52-week range ($8.63–$17.53), indicating strong momentum and near-term overextension. This positioning near the highs suggests bullish sentiment but also raises caution for potential pullbacks. Short-term momentum remains positive, with a 1-month gain of 6.4% and a 3-month gain of 24.3%, outpacing the S&P 500's 1-month decline of 1.25% and 3-month gain of 13.56%. The relative strength versus the market is 7.7% over 1 month and 10.7% over 3 months, confirming the stock's outperformance. However, the 1-month gain of 6.4% is a deceleration from the 3-month pace, suggesting a possible consolidation phase. The 52-week high of $17.53 acts as key resistance; a breakout above this level would signal further upside, while support lies near the 52-week low of $8.63. The stock's beta of 0.90 indicates slightly lower volatility than the market, which is unusual for a generic pharma name and may reflect its defensive characteristics.
Beta
0.90
0.90x market volatility
Max Drawdown
-19.6%
Largest decline past year
52-Week Range
$9-$18
Price range past year
Annual Return
+80.3%
Cumulative gain past year
| Period | VTRS Return | S&P 500 |
|---|---|---|
| 1m | +5.8% | +1.9% |
| 3m | +27.7% | +14.0% |
| 6m | +34.8% | +8.9% |
| 1y | +80.3% | +20.1% |
| ytd | +34.8% | +10.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
VTRS Fundamental Analysis
Revenue in Q4 2025 was $3.70 billion, up 4.97% year-over-year from $3.53 billion, marking a return to growth after declines in prior quarters. The revenue mix shows Brands contributing $2.35 billion (63%) and Generics $1.34 billion (37%), with the Brands segment driving growth. However, the company reported a net loss of $340 million in Q4 2025, though this improved from a loss of $517 million in Q4 2024. Gross margin was 30.6% in Q4 2025, down from 34.4% a year earlier, indicating margin compression. The company remains unprofitable on a trailing twelve-month basis, with a net margin of -24.6%, but the trajectory shows narrowing losses. Free cash flow generation is strong, with TTM free cash flow of $1.82 billion and a free cash flow per share of $0.48. The debt-to-equity ratio is 1.0, and the current ratio is 1.30, indicating adequate liquidity. However, the negative ROE of -23.9% reflects ongoing profitability challenges, though the company's cash flow from operations of $816 million in Q4 2025 provides a cushion for debt servicing and investment.
Quarterly Revenue
$3.7B
2025-12
Revenue YoY Growth
+0.04%
YoY Comparison
Gross Margin
+0.30%
Latest Quarter
Free Cash Flow
$1.8B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is VTRS Overvalued?
Given negative net income, we use the price-to-sales (PS) ratio as the primary valuation metric. The trailing PS ratio is 1.02x, while the forward PS ratio is not explicitly provided but can be estimated from revenue estimates. The EV/Sales multiple of 2.17x provides a more comprehensive view. Compared to the industry average (not provided), Viatris trades at a discount to the broader pharma sector, which typically commands higher multiples due to growth and profitability. The stock's PB ratio of 0.99x suggests it is trading near book value, which is common for generic drug companies. Historically, Viatris's PS ratio has ranged from 2.5x to 4.2x over the past five years, and the current 1.02x is near the bottom of that range, indicating a potential value opportunity. However, the low multiple reflects the company's lack of profitability and margin pressures. The forward PE of 6.27x (based on positive expected earnings) implies the market expects a return to profitability, but the negative PEG ratio of -0.009 suggests high uncertainty.
PE
-4.1x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -569x~37x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-70.6x
Enterprise Value Multiple